Teva extends Codexis biocatalyst deal

- Last updated on GMT

Related tags: Generic drug

Teva will continue to use Codexis’ biocatalysis technology for key processing steps in the production of four generic drugs under a revised agreement announced last week.

The firms have worked on the project since January last year with Codexis using its proprietary MolecularBreeding technology to develop custom “super enzymes​” to accelerate Teva’s production processes.

While further details of deal, or the drugs being produced, were not disclosed Codexis’ CEO, Alan Shaw, said the: "Expansion of our relationship with Teva from one to four products in under a year demonstrates the value of Codexis technology in today's competitive pharmaceuticals market​."

Teva and Codexis’ first research collaboration was signed in late 2004, with the Israeli generics giant licensing exclusive rights to commercialise the process in return for providing research funding.

Related news

Show more

Related products

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers